Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Halofantrine Hydrochloride

FDA-approved product (tablet, oral), marketed as Halfan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Halofantrine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antimalarials
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BX01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Halofantrine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Halofantrine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RSV Vaccination to Reduce Recurrent AECOPD

    NCT07508644 · start 2027-07-01

    Registered record
    Registry ID
    NCT07508644
    Conditions
    COPD; RSV
    Interventions
    RSV vaccination (Arexvy, GlaxoSmithKline)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2027-07-01
    Completion
    2030-12-31
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD; RSV
    InterventionRSV vaccination (Arexvy, GlaxoSmithKline)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)

    NCT07240558 · start 2025-11-03

    Registered record
    Registry ID
    NCT07240558
    Conditions
    Influenza (Pandemic); Avian Influenza; Vaccination
    Interventions
    H5N1 vaccine (Arepanrix, GSK); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-11-03
    Completion
    2026-12-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfluenza (Pandemic); Avian Influenza; Vaccination
    InterventionH5N1 vaccine (Arepanrix, GSK); Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

    NCT06932523 · start 2025-04-04

    Registered record
    Registry ID
    NCT06932523
    Conditions
    Herpes Zoster (HZ)
    Interventions
    Recombinant herpes zoster vaccine with low-dose adjuvant; Recombinant herpes zoster vaccine with high-dose adjuvant; Low-dose adjuvant; High-dose adjuvant; Shingrix (GSK); Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-04-04
    Completion
    2027-12-31
    Enrolment
    645

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Zoster (HZ)
    InterventionRecombinant herpes zoster vaccine with low-dose adjuvant; Recombinant herpes zoster vaccine with high-dose adjuvant; Low-dose adjuvant; High-dose adjuvant +2 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.

    NCT06385600 · start 2024-05-20

    Registered record
    Registry ID
    NCT06385600
    Conditions
    Severe Pre-eclampsia
    Interventions
    Labetalol; Phentolamine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-05-20
    Completion
    2026-03-20
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Pre-eclampsia
    InterventionLabetalol; Phentolamine
    PhaseNot applicable
    Registry statusUnknown

  • Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People

    NCT06675851 · start 2022-12-01

    Registered record
    Registry ID
    NCT06675851
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline; Cipralex (escitalopram)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-12-01
    Completion
    2026-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    InterventionWELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline; Cipralex (escitalopram)
    PhasePhase 4
    Registry statusRecruiting

  • Prophylaxis Against Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

    NCT06017167 · start 2022-09-15

    Registered record
    Registry ID
    NCT06017167
    Conditions
    Postoperative Nausea and Vomiting; Laparoscopic Cholecystectomy
    Interventions
    Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .; Ondansetron 4mg + dexamethasone 8mg + normal saline.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-09-15
    Completion
    2023-10
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting; Laparoscopic Cholecystectomy
    InterventionOndansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline .; Ondansetron 4mg + dexamethasone 8mg + normal saline.
    PhasePhase 2
    Registry statusUnknown

  • Dental Biofilm Control During Orthodontic Treatment

    NCT05532241 · start 2021-11-01

    Registered record
    Registry ID
    NCT05532241
    Conditions
    Gingivitis; Malocclusion
    Interventions
    fixed metal orthodontic appliance; fixed non-metal orthodontic appliance; oral hygiene; Chlorhexidine mouthwash
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-11-01
    Completion
    2026-06-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGingivitis; Malocclusion
    Interventionfixed metal orthodontic appliance; fixed non-metal orthodontic appliance; oral hygiene; Chlorhexidine mouthwash
    PhasePhase 3
    Registry statusActive not recruiting

  • Evaluate the Ability of dOFM for BE Testing of Topically Applied Diclofenac Sodium Products in Healthy Subjects

    NCT04592016 · start 2020-10-08

    Registered record
    Registry ID
    NCT04592016
    Conditions
    Healthy
    Interventions
    Voltaren - Diclofenac sodium gel 1% (GSK, USA); Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA); Diclofenac sodium gel 1% (Perrigo, USA); Dermal open flow microperfusion - Pilot; Dermal open flow microperfusion - Pivotal; Blood sampling - Pilot; Blood sampling - Pivotal
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-10-08
    Completion
    2021-08-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionVoltaren - Diclofenac sodium gel 1% (GSK, USA); Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA); Diclofenac sodium gel 1% (Perrigo, USA); Dermal open flow microperfusion - Pilot +3 more
    PhaseNot applicable
    Registry statusCompleted

  • Pain Management During Screening for Retinopathy of Prematurity

    NCT04767178 · start 2020-01-01

    Registered record
    Registry ID
    NCT04767178
    Conditions
    Retinopathy of Prematurity; Pain Management
    Interventions
    Ibuprofen (Sanofi, Istanbul, Turkey); Paracetamol (GlaxoSmithKline, Istanbul, Turkey)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2020-08-15
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinopathy of Prematurity; Pain Management
    InterventionIbuprofen (Sanofi, Istanbul, Turkey); Paracetamol (GlaxoSmithKline, Istanbul, Turkey)
    PhaseNot recorded
    Registry statusCompleted

  • Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy.

    NCT04054830 · start 2019-08-01

    Registered record
    Registry ID
    NCT04054830
    Conditions
    Glaucoma
    Interventions
    Voltaren Ophtha 1 mg/ml, GSK; Monopex 1 mg/ml, Théa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-08-01
    Completion
    2023-07
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma
    InterventionVoltaren Ophtha 1 mg/ml, GSK; Monopex 1 mg/ml, Théa
    PhasePhase 4
    Registry statusUnknown

  • Oral Health-related Quality of Life and Masticatory Function After Using Denture Adhesive and Denture Liner

    NCT04942262 · start 2019-01-31

    Registered record
    Registry ID
    NCT04942262
    Conditions
    Complete Denture; Complete Edentulism
    Interventions
    denture adhesive (Polident®, GlaxoSmithKline, Ireland)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-01-31
    Completion
    2020-04-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplete Denture; Complete Edentulism
    Interventiondenture adhesive (Polident®, GlaxoSmithKline, Ireland)
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Three Antibiotic Protocols in Prevention of Infection in Dental Implant Surgery

    NCT04620018 · start 2016-09-30

    Registered record
    Registry ID
    NCT04620018
    Conditions
    Dental Implant Failed
    Interventions
    Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-09-30
    Completion
    2020-09-01
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDental Implant Failed
    InterventionAmoxicillin
    PhaseNot applicable
    Registry statusCompleted

  • Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance

    NCT03465488 · start 2016-08-15

    Registered record
    Registry ID
    NCT03465488
    Conditions
    Soil-transmitted Helminth Infections
    Interventions
    Albendazole Pill 400mg (GSK)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-08-15
    Completion
    2019-09-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSoil-transmitted Helminth Infections
    InterventionAlbendazole Pill 400mg (GSK)
    PhaseNot applicable
    Registry statusCompleted

  • Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures

    NCT04214938 · start 2016-02-01

    Registered record
    Registry ID
    NCT04214938
    Conditions
    Nasopharyngeal Diseases
    Interventions
    Intranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02-01
    Completion
    2019-01-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasopharyngeal Diseases
    InterventionIntranasal solutions application were done including one solution for per patient before nasoendoscopy procedure according to randomization
    PhasePhase 4
    Registry statusCompleted

  • Cytogenetic Damage in Buccal Cells Caused by Toothpaste

    NCT03325400 · start 2016-01-01

    Registered record
    Registry ID
    NCT03325400
    Conditions
    Toxicity
    Interventions
    Toothpaste non-fluoride and fluoride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-01-01
    Completion
    2016-07-20
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionToxicity
    InterventionToothpaste non-fluoride and fluoride
    PhaseNot applicable
    Registry statusCompleted